Abstract
High dose oestrogen therapy was used as a treatment for postmenopausal patients with breast cancer from the 1950s until the introduction of the safer antioestrogen, tamoxifen in the 1970s. The anti-tumour mechanism of high dose oestrogen therapy remained unknown. There was no enthusiasm to study these signal transduction pathways as oestrogen therapy has almost completely been eliminated from the treatment paradigm. Current use of tamoxifen and the aromatase inhibitors seek to create oestrogen deprivation that prevents the growth of oestrogen stimulated oestrogen receptor (ER) positive breast cancer cells. However, acquired resistance to antihormonal therapy does occur, but it is through investigation of laboratory models that a vulnerability of the cancer cell has been discovered and is being investigated to provide new opportunities in therapy with the potential for discovering new cancer-specific apoptotic drugs. Laboratory models of resistance to raloxifene and tamoxifen, the selective oestrogen receptor modulators (SERMs) and aromatase inhibitors demonstrate an evolution of drug resistance so that after many years of oestrogen deprivation, the ER positive cancer cell reconfigures the survival signal transduction pathways so oestrogen now becomes an apoptotic trigger rather than a survival signal. Current efforts are evaluating the mechanisms of oestrogen-induced apoptosis and how this new biology of oestrogen action can be amplified and enhanced, thereby increasing the value of this therapeutic opportunity for the treatment of breast cancer. Several synergistic approaches to therapeutic enhancement are being advanced which involve drug combinations to impair survival signaling with the use of specific agents and to impair bcl-2 that protects the cancer cell from apoptosis. We highlight the historical understanding of oestrogens role in cell survival and death and specifically illustrate the progress that has been made in the last five years to understand the mechanisms of oestrogen-induced apoptosis. There are opportunities to harness knowledge from this new signal transduction pathway to discover the precise mechanism of this oestrogen-induced apoptotic trigger. Indeed, the new biology of oestrogen action also has significance for understanding the physiology of bone remodeling. Thus, the pathway has a broad appeal in both physiology and cancer research.
Keywords: Breast cancer, oestrogen receptor, oestrogen action, apoptosis, tamoxifen, selective oestrogen receptor modulators
Current Signal Transduction Therapy
Title: The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Volume: 4 Issue: 2
Author(s): Philipp Y. Maximov, Joan S. Lewis-Wambi and Virgil Craig Jordan
Affiliation:
Keywords: Breast cancer, oestrogen receptor, oestrogen action, apoptosis, tamoxifen, selective oestrogen receptor modulators
Abstract: High dose oestrogen therapy was used as a treatment for postmenopausal patients with breast cancer from the 1950s until the introduction of the safer antioestrogen, tamoxifen in the 1970s. The anti-tumour mechanism of high dose oestrogen therapy remained unknown. There was no enthusiasm to study these signal transduction pathways as oestrogen therapy has almost completely been eliminated from the treatment paradigm. Current use of tamoxifen and the aromatase inhibitors seek to create oestrogen deprivation that prevents the growth of oestrogen stimulated oestrogen receptor (ER) positive breast cancer cells. However, acquired resistance to antihormonal therapy does occur, but it is through investigation of laboratory models that a vulnerability of the cancer cell has been discovered and is being investigated to provide new opportunities in therapy with the potential for discovering new cancer-specific apoptotic drugs. Laboratory models of resistance to raloxifene and tamoxifen, the selective oestrogen receptor modulators (SERMs) and aromatase inhibitors demonstrate an evolution of drug resistance so that after many years of oestrogen deprivation, the ER positive cancer cell reconfigures the survival signal transduction pathways so oestrogen now becomes an apoptotic trigger rather than a survival signal. Current efforts are evaluating the mechanisms of oestrogen-induced apoptosis and how this new biology of oestrogen action can be amplified and enhanced, thereby increasing the value of this therapeutic opportunity for the treatment of breast cancer. Several synergistic approaches to therapeutic enhancement are being advanced which involve drug combinations to impair survival signaling with the use of specific agents and to impair bcl-2 that protects the cancer cell from apoptosis. We highlight the historical understanding of oestrogens role in cell survival and death and specifically illustrate the progress that has been made in the last five years to understand the mechanisms of oestrogen-induced apoptosis. There are opportunities to harness knowledge from this new signal transduction pathway to discover the precise mechanism of this oestrogen-induced apoptotic trigger. Indeed, the new biology of oestrogen action also has significance for understanding the physiology of bone remodeling. Thus, the pathway has a broad appeal in both physiology and cancer research.
Export Options
About this article
Cite this article as:
Maximov Y. Philipp, Lewis-Wambi S. Joan and Jordan Craig Virgil, The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis, Current Signal Transduction Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157436209788167484
DOI https://dx.doi.org/10.2174/157436209788167484 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents The Impact of Antioxidants from the Diet on Breast Cancer Cells Monitored by Raman Microspectroscopy
Letters in Drug Design & Discovery Genetic Databases and their Potential in Pharmacogenomics
Current Pharmaceutical Design Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone
Anti-Cancer Agents in Medicinal Chemistry Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Current Medicinal Chemistry Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Flavonoids: Prospective Drug Candidates
Mini-Reviews in Medicinal Chemistry Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Immunology of O-Glycosylated Proteins: Approaches to the Design of a MUC1 Glycopeptide-Based Tumor Vaccine
Current Protein & Peptide Science